Stock Events

Stock Events

Vigil Neuroscience 

$8.05
13
+$0+0% Monday 20:00

Statistics

Day High
8.05
Day Low
8.05
52W High
8.1
52W Low
1.31
Volume
5,503,751
Avg. Volume
1,650,224
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

5AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.61
-0.4
-0.2
0
Expected EPS
-0.46
Actual EPS
-0.56

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-84.26MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VIGL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a leading biotech company focusing on neurodegenerative diseases, directly competing with Vigil Neuroscience's focus on microglial biology and neurodegeneration.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including treatments for neurological diseases, competing in the neurodegenerative space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for genetically defined diseases, including neurodegenerative disorders, making it a competitor.
Palatin Technologies
PTN
Mkt Cap2.45M
Palatin Technologies is engaged in developing targeted, receptor-specific peptide therapeutics for diseases with significant unmet medical need, including neurological disorders.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. focuses on developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, directly competing with Vigil.
AC Immune SA
ACIU
Mkt Cap340.03M
AC Immune SA specializes in precision medicine for neurodegenerative diseases, including Alzheimer's, directly competing in Vigil's focus area.
AnaptysBio
ANAB
Mkt Cap1.02B
AnaptysBio is involved in developing therapeutic antibodies for inflammation and immuno-oncology but has interests in neuroinflammatory conditions, indirectly competing with Vigil.

About

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
Employees
69
Country
US
ISIN
US92673K1088

Listings

0 Comments

Share your thoughts

FAQ

What is Vigil Neuroscience stock price today?▼
The current price of VIGL is $8.05 USD — it has increased by +0% in the past 24 hours. Watch Vigil Neuroscience stock price performance more closely on the chart.
What is Vigil Neuroscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vigil Neuroscience stocks are traded under the ticker VIGL.
Is Vigil Neuroscience stock price growing?▼
VIGL stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Vigil Neuroscience has showed a +382.04% increase.
What were Vigil Neuroscience earnings last quarter?▼
VIGL earnings for the last quarter are -0.56 USD per share, whereas the estimation was -0.46 USD resulting in a -21.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vigil Neuroscience revenue for the last year?▼
Vigil Neuroscience revenue for the last year amounts to 0 USD.
What is Vigil Neuroscience net income for the last year?▼
VIGL net income for the last year is -84.26M USD.
How many employees does Vigil Neuroscience have?▼
As of April 03, 2026, the company has 69 employees.
In which sector is Vigil Neuroscience located?▼
Vigil Neuroscience operates in the Health Care sector.
When did Vigil Neuroscience complete a stock split?▼
Vigil Neuroscience has not had any recent stock splits.
Where is Vigil Neuroscience headquartered?▼
Vigil Neuroscience is headquartered in Watertown, US.